<DOC>
	<DOCNO>NCT03082014</DOCNO>
	<brief_summary>Multicentre , multinational , prospective randomise , open-label , 3 sequence crossover phase III b clinical trial blind endpoint assessment ( PROBE-design ) - 75 patient sporadic small vessel disease ( SVDs ) - 30 patient cerebral autosomal dominant arteriopathy subcortical infarct leukoencephalopathy ( CADASIL )</brief_summary>
	<brief_title>Effects Amlodipine Other Blood Pressure Lowering Agents Microvascular Function</brief_title>
	<detailed_description>TREAT-SVDs carry multicentre open label trial five trial site across 3 European country : Germany , Netherlands , United Kingdom . Patients meet eligibility criterion randomly allocate one three sequence antihypertensive treatment give open-label oral medication standard dose follow order Arm A : Amlodipine &gt; Losartan &gt; Atenolol Arm B : Atenolol &gt; Amlodipine &gt; Losartan Arm C : Losartan &gt; Atenolol &gt; Amlodipine . The study start two week run-in phase . During first two week , patient allow take antihypertensive drug except rescue medication . After run-in period , every patient take subsequently three different antihypertensive drug ( drug separate drug class ) accord randomly assign arm . Each study drug administer four week . Patients monitor telemetrically dedicate BP device whole trial period 14 week .</detailed_description>
	<mesh_term>Cerebral Small Vessel Diseases</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients may enrol trial follow criterion meet : Symptomatic SVD define History clinical lacunar stroke last 5 year correspond recent small subcortical infarct visible MRI scan CT scan* compatible clinical syndrome . *On MRI , recent infarct define diffusionweighted imaging ( DWI ) lesion acute MRI scan . On CT , recent infarct define novel infarct CT within 3 week event visible admission CT. cognitive impairment define visit memory clinic cognitive complaint , clinical dementia rating ( CDR ) score ≥ 0.5 , capacity consent , confluent deep white matter hyperintensities ( WMH ) MRI ( define Fazekas scale deep WMH score ≥ 2 ) diagnosis CADASIL establish molecular genetic test NOTCH3 gene ( presence archetypical , cysteineaffecting mutation ) presence granular osmiophilic material ultrastructural , electron microscopy analysis skin biopsy Indication antihypertensive treatment ( defined meet one follow ) : Hypertension define SBP ≥ 140 mmHg diastolic BP ( DBP ) ≥ 90 mmHg without antihypertensive treatment use antihypertensive drug previously diagnose hypertension Prior history stroke transient ischaemic attack ( TIA ) Age 18 year old Written inform consent Patients exclude trial follow reason : Inclusion criterion meet Unwillingness inability give write consent Pregnant breastfeeding woman , woman childbearing age take contraception . Acceptable contraception woman childbearing age `` highly effective '' contraceptive measure define Clinical Trials Facilitation Group include combine ( oestrogen progesterone contain ) progesteroneonly contraception associate inhibition ovulation , intrauterine device , bilateral tubal occlusion . Contraindications MRI ( pacemaker , aneurysm clip , cochlear implant etc . ) Other major neurological psychiatric condition affect brain interfere trial design ( e.g . multiple sclerosis ) In case clinical lacunar stroke syndrome cause stroke ≥ 50 % luminal stenosis ( NASCET ) large artery supply area ischaemia majorrisk cardioembolic source embolism ( permanent paroxysmal atrial fibrillation , sustain atrial flutter , intracardiac thrombus , prosthetic cardiac valve , atrial myxoma cardiac tumour , mitral stenosis , recent ( &lt; 4 week ) myocardial infarction , leave ventricular ejection fraction le 30 % , valvular vegetation , infective endocarditis ) specific cause stroke identify ( e.g . arteritis , dissection , migraine/vasospasm , drug misuse ) Other stroke risk factor require immediate intervention would preclude involvement trial Renal impairment ( eGFR &lt; 35ml/min ) Life expectancy &lt; 2 year Use &gt; 2 antihypertensive drug appropriate BP control Contraindications apply antihypertensive drug know Severe aortic stenosis Bilateral renal artery stenosis Severe arterial circulatory disorder Atrioventricular block II° III° sick sinus syndrome Heart failure ( NYHA III IV ) Bradycardia , rest heart rate &lt; 50/min Bronchospastic disease severe bronchial asthma Severe hepatic dysfunction liver cirrhosis Use monoamine oxidase ( MAO ) Ablockers Use simvastatin &gt; 20mg/d Metabolic acidosis Disturbed electrolyte homeostasis hypercalcaemia , hypokalaemia , hyponatraemia Symptomatic hyperuricaemia ( gout )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Cerebrovascular Reactivity</keyword>
	<keyword>Blood Pressure Variability</keyword>
</DOC>